Home » Stocks » Seelos Therapeutics

Seelos Therapeutics, Inc. (SEEL)

Stock Price: $1.06 USD 0.00 (0.00%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $1.04 -0.02 (-1.89%) Aug 13, 7:59 PM

Stock Price Chart

Key Info

Market Cap 47.65M
Revenue (ttm) 375,000
Net Income (ttm) -20.58M
Shares Out 44.95M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $1.06
Previous Close $1.06
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.07
Day's Range 1.03 - 1.07
Day's Volume 244,564
52-Week Range 0.42 - 1.98

More Stats

Market Cap 47.65M
Enterprise Value 34.96M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 44.95M
Float 37.93M
EPS (basic) -0.63
EPS (diluted) -0.77
FCF / Share -0.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 602,655
Short Ratio 0.39
Short % of Float 0.97%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 127.06
PB Ratio 7.38
Revenue 375,000
Operating Income -22.91M
Net Income -20.58M
Free Cash Flow -17.79M
Net Cash 12.69M
Net Cash / Share 0.28
Gross Margin 100.00%
Operating Margin -6,110.40%
Profit Margin -5,486.70%
FCF Margin -4,743.47%
ROA -118.40%
ROE -419.81%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.00*
(654.72% upside)
Low
4.00
Current: $1.06
High
12.00
Target: 8.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.38---4.849.262.517.953.604.97
Revenue Growth-----47.74%268.74%-68.4%120.51%-27.55%-
Gross Profit0.38---3.928.34-0.123.711.751.03
Operating Income-29.75-3.18-10.68-13.67-21.35-22.61-17.62-25.26-15.53-21.40
Net Income-51.26-3.480.32-7.43-19.02-21.79-16.94-31.77-18.12-29.51
Shares Outstanding20.313.080.400.220.170.130.110.090.070.04
Earnings Per Share-2.52-1.130.81-34.50-114.91-165.02-147.02-348.04-270.03-747.08
Operating Cash Flow-19.31-1.58-10.47-13.07-22.64-18.02-15.07-14.38-9.72-6.89
Capital Expenditures----0.02-0.33-0.583.08-0.44-0.26-0.44
Free Cash Flow-19.31-1.58-10.47-13.08-22.97-18.60-11.98-14.82-9.98-7.33
Cash & Equivalents10.260.046.332.094.1711.6921.7415.187.499.75
Total Debt-2.44-6.659.404.782.603.414.004.53
Net Cash / Debt10.26-2.406.33-4.56-5.236.9119.1411.773.495.22
Assets11.100.196.714.707.7814.8123.3123.8816.6218.86
Liabilities11.104.902.3412.2217.7312.8912.3417.2611.807.30
Book Value-0.01-4.714.37-7.52-9.941.9210.976.624.8211.57
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Seelos Therapeutics, Inc.
Country United States
Employees 6
CEO Raj Mehra

Stock Information

Ticker Symbol SEEL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SEEL

Description

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with Parkinson's disease or Lewy Body Dementia; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and orphan indications; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. The company was founded in 2016 and is headquartered in New York, New York.